Objective: To investigate 5-year postoperative results of photoselective vaporization of the prostate using the 120-W GreenLight High Performance System photoselective vaporization of the prostate (HPS-PVP) for treating benign prostate hyperplasia Methods: A total 208 men who underwent HPS-PVP and were followed up for five years were analyzed retrospectively. Surgical outcomes were assessed by the ratio of the IPSS/QoL, the difference in Qmax/PVR and the difference of the prostate volume by transrectal ultrasonography before surgery and at 6, 12, 36 and 60 months postoperatively. The presence of postoperative complications was verified at every follow-up visit. Results: Preoperative parameters such as mean age, prostate volume, IPSS, QoL, Qmax and PVR, were 67.9±8.2 years, 48.4±26.3 mL, 20.4±8.7, 4.0±9.2±3.5 mL/s, and 81.3±92.0 mL, respectively. Perioperatively, mean operative time, lasing time, used energy, and postoperative urethral catheter indwelling time were 67.4±45.9 minutes, 26.7±29.3 minutes, 89.6±82.5 kJ and 24.5±11.0 hours, separately. There were significant improvements in all outcome measures after 3, 12, 36 and 60 months. Forty-nine (23.6%) patients had immediate postoperative complications which were managed successfully nonsurgical methods. There were no transfusion cases. A single case (1.5%) showed mild urethral stricture with voiding difficulty 12 months postoperatively and required urethral dilation using panendoscopy. Conclusions: HPS-PVP is an effective and safe procedure for treating benign prostatic hyperplasia. 
a 120 W GreenLight laser with HoLEP in a small prostate volume. Methods: Patients who underwent PVP or HoLEP surgery for BPH at our institutions were reviewed from May 2009 to December 2014 in this retrospective study. Among them, patients with prostate volumes <40 mL based on preoperative trans-rectal ultrasonography were included in this study. Peri-operative and post-operative parameterssuch as International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), post-void residual urine volume (PVR), and complicationswere compared between the groups. Results: PVP was performed in 176 patients and HoLEP in162 patients. Preoperative demographic data were similar in both groups, with the exception of PVR. Operative time and catheter duration did not show significant difference. Significant improvements compared to preoperative values were verified at the postoperative evaluation in both groups in terms of IPSS, QoL, Qmax, and PVR. Comparison of the postoperative parameters between the PVP and HoLEP groups demonstrated no significant difference, with the exception of IPSS voiding subscore at one month postoperatively (5.9 vs. 3.8, P<0.001). There was no significant difference in postoperative complications between the two groups. Conclusions: Our data suggest that PVP and HoLEP are efficient and safe surgical treatment options for patients with small prostate volume. Objective: Transurethral resection of the prostate (TURP) is a gold standard surgical procedure to treat the bothersome BPH induced LUTS within the range less than 100 mL. Just after a complete resection of the prostate, especially the posterior portion, however, the insertion of a Foley catheter could be very difficult or impossible, even while using a stylet. We demonstrates two techniques to more easily insert a Foley catheter just after performing the TURP. Methods: Among 152 men who underwent TURP by bipolar surgical unit, we found that 27 men experienced the Foley catheter getting stuck while being inserted in the usual way. This was because of the excessive resection of the posterior portion of the prostate just underneath the bladder neck. In the 27 men, we then inserted a 20 Fr sized Foley catheter through an anterior-and upwardmovement of posterior prostatic capsule by pressing the rectal wall using a finger and a flexible urethral catheter instead of a stylet. We filmed the inside view of the patient who underwent suprapubic open prostatectomy and transurethral adjustment continuously. Results: For the case of the 27 men concerned, by adopting this novel technique, the Foley catheter was completely and safely inserted just after the TURP without any complication.
Conclusions:
The two techniques to insert a Foley catheter just after the TURP can be performed safely within the set time limit without having to use any other medical device such as the stylet.
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